ReviewThrombosis journal2026
Two decades of prenatal diagnosis in hemophilia A and B: a systematic review of global trends and current practices.
Review in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemophilia A and B are severe X-linked bleeding disorders caused by variants in the F8 and F9 genes, respectively. Over the past two decades, prenatal diagnosis (PND) has become an essential component of hemophilia management, yet global practices remain heterogeneous. This study aimed to analyze worldwide trends, methodologies, and outcomes of PND for hemophilia A and B, highlighting advances, disparities, and future needs. MAIN BODY: Following PRISMA guidelines, PubMed, Scopus, Embase, and Web of Science were searched for relevant publications between January 2005 and September 2025. Twenty-four eligible studies encompassing 969 pregnancies were included. Among them, 78.3% (n = 759) were hemophilia A carriers and 16.3% (n = 158) hemophilia B carriers. Amniocentesis (45.8%) and chorionic villus sampling (41.6%) were the most frequently applied techniques, while non-invasive cell-free DNA testing was reported in 20.8% of studies as an emerging alternative. Direct sequencing and PCR-based assays were each used in 45.8% of cases, followed by linkage analysis in 33.3%. Out of 423 fetuses analyzed, 318 (~ 75%) were affected, including 245 (~ 58%) with hemophilia A, 47 (~ 11%) with hemophilia B, and for 26 (6%) the specific type of hemophilia was not reported. Pregnancy outcomes were reported in 10 studies: 45 (14%) affected pregnancies were terminated, 15 (4.7%) were continued to term, and data were unavailable for 81% of cases. Most publications originated from China (n = 8; 33.3%), Italy (n = 5; 20.8%), and India (n = 3; 12.5%), underscoring global disparities in access and reporting. Over time, a clear transition from linkage analysis to molecular sequencing was observed, alongside the early adoption of next-generation and digital PCR techniques.
conclusionsThis study reveals remarkable progress in molecular diagnostics that has substantially improved PND accuracy for hemophilia. However, regional inequities, limited reporting of pregnancy outcomes, and restricted access to advanced technologies persist. Establishing harmonized international guidelines, expanding non-invasive testing validation, and promoting equitable access to genetic services are crucial steps to ensure that future PND practices support informed reproductive decisions and global health equity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.